

Amendments to the Claims

Claims 1-19 (Cancelled)

Claim 20 (Currently amended): A method for increasing gene transfer to recipient cells comprising:
introducing to said recipient cell a first replication incompetent adenoviral vector having an E1 deletion, and a second replication incompetent adenoviral vector having an E4 deletion, wherein one or both of said vectors comprise a nucleotide sequence the expression of which is desired in said recipient cell, wherein said first and second adenoviral vectors are transcomplementary, so that upon cotransduction viral replication is enabled, wherein each vector is ~~capable of sustained viral replication and capable of being produced independently of each other in separate trans-complementing packaging cell lines, thereby providing individual higher titers than vectors that are produced co-dependently on the same packaging cell line.~~

Claim 21 (Original): The method of claim 20 wherein said nucleotide sequence is an expression construct.

Claims 22-23 (Cancelled)

Claim 24 (Currently amended): The method of claims ~~22 or 23~~ 20 wherein one or both of said vectors is an E3 mutant.

Claim 25 (Currently amended): The method of claim ~~23~~ 20 wherein said second vector is recombinant 1014.

Claim 26 (Currently amended): The method of claim ~~22~~ 20 wherein said first vector is AVC2.TK.

Claim 27 (Original): The method of claim 20 wherein said nucleotide sequence encodes green fluorescent protein.

Claim 28 (Previously presented): The method of claim 20 wherein said sequence is a tumor suppressor gene.

Claim 29 (Previously presented): The method of claim 20 wherein said sequence is a tumor suicide gene.

Claims 30-36 (Cancelled)

Claim 37 (Withdrawn): A method of inducing tumor cell regression comprising: introducing to said tumor cell a first replication incompetent adenoviral vector, said vector including a nucleotide sequence which encodes a suicide gene, the expression of which is desired in said recipient tumor cell, and a second replication incompetent adenoviral vector, said vector comprising a suicide gene the expression of which is desired in said recipient cell, wherein said first and second adenoviral vectors are transcomplementary.

Claim 38 (Withdrawn): The method of claim 37 wherein said suicide gene is a sodium iodide symporter gene.

Claim 39 (Withdrawn): The method of claim 37 wherein said suicide gene is a herpes simplex virus thymidine kinase gene.

Claim 40 (Withdrawn): The method of claim 39 further comprising the step of: introducing an agent to activate said suicide gene.

Claim 41 (Withdrawn): The method of claim 40 wherein said agent is radioactive iodide.

Claim 42 (Withdrawn): A method of inducing tumor cell regression comprising: introducing to said tumor cell a first replication incompetent adenoviral vector, said vector including a nucleotide sequence which encodes a thyroid sodium iodide symporter gene, the expression of which is desired in said recipient tumor cell, and a second replication incompetent adenoviral vector, said vector comprising a sodium iodide symporter gene the expression of which is desired in said recipient cell, wherein said first and second adenoviral vectors are transcomplementary, and thereafter exposing said tumor cells to radioactive iodide.

Claims 43-46 (Cancelled)